Tokai Pharmaceuticals Appoints Adrian M. Senderowicz, M.D., as Chief Medical Officer and Vice President, Medical Development
8/9/2012 10:20:55 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced the appointment of Adrian M. Senderowicz, M.D., to the position of chief medical officer and vice president, medical development. Dr. Senderowicz brings 15 years’ experience as a board-certified medical oncologist with significant industry, clinical, academic and U.S. regulatory expertise. Tokai’s lead candidate, galeterone (TOK-001), recently received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the potential treatment of metastatic castration-resistant prostate cancer (CRPC), an advanced and difficult-to-treat form of prostate cancer that occurs when the disease progresses despite the use of androgen deprivation therapy.